Elsie DiBella joined Kisbee in May 2022 as the Senior Vice President of Technical Operations, bringing more than 25 years of industry experience in biologics development and manufacturing. Elsie has worked on more than 20 biologics from the preclinical stage through post-approval changes.
Most recently, she was the Vice President of Manufacturing and Development at ContraFect Corporation. Prior to joining ContraFect, Elsie was the Head of Biologics Process and Analytical Development at Momenta Pharmaceutical overseeing a portfolio of both novel and biosimilar biologics. Previously, she held roles of increasing responsibility within Process Development and Manufacturing Sciences at Shire Pharmaceuticals, Centocor Pharmaceuticals and Bristol-Myers Squibb. While at Shire Pharmaceuticals, Elsie contributed to global marketing authorization submissions and post-approval supplements for VPRIV®, Replagal® and Elaprase®. While at Centocor Pharmaceuticals, she was responsible for the late-stage purification process development of and contributed to the BLAs for Simponi® and Stelara®.
Elsie received her B.S. in Chemistry from Bates College and her PhD in Biophysical Chemistry from Cornell University in the laboratory of late Harold Scheraga.